DUSP4 is an Oncogenic Gene for the Carcinogenesis of Clear cell Renal Cell Carcinoma

Xianyou Zeng
The affiliated hospital of jinggangshan university

Changyan Zhu
900th Hospital of PLA

Xianxin Zhu (✉ zxxgzrm@aliyun.com)
Ganzhou People's Hospital  https://orcid.org/0000-0003-1196-6858

Short Report

Keywords: DUSP4, CCRCC, Proliferation, Migration, Tumorigenicity

DOI: https://doi.org/10.21203/rs.3.rs-179349/v1

License: ☑️ ☐ This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract
DUSP4 is considered as an oncogenic gene. However, the effect of DUSP4 on the oncogenesis of Clear cell Renal cell carcinoma (CCRCC) is still unclear. In this study, we explored the expression pattern of DUSP4 in CCRCC cancer tissues and CCRCC cell lines by qRT-PCR. Furthermore, we investigated the roles of DUSP4 in CCRCC using gain-of-function and loss-of-function assays. Here, DUSP4 mRNA levels were significantly increased in CCRCC tissues and cell lines. DUSP4 overexpression promotes the proliferation, migration and tumorigenicity of CCRCC cells while DUSP4 silencing showed the opposite effects. DUSP4 serves as an oncogenic gene in CCRCC carcinogenesis, indicating the potential value of DUSP4 in the diagnosis and treatment of CCRCC.

Introduction
Here, we focused on DUSP4, whose expression is responsible for the carcinogenesis of various malignancies [9, 13–17]. With the further study on the role of DUSP4 gene in tumors, it was found that DUSP4 is closely related to CCRCC. Remarkably, high DUSP4 levels in CCRCC cancer tissues are displayed in the GEPIA of TCGA database. However, the relationship between CCRCC carcinogenesis and DUSP4 is still unknown. In our study, DUSP4 expression in CCRCC tissues and cell lines was higher than that in non-cancer tissues and normal renal tubular epithelial cell line, respectively. Importantly, with the invasion or metastasis of CCRCC, DUSP4 levels in cancer tissues was further increased. The analyses related to the correlation between DUSP4 levels and the clinicopathological features showed that high DUSP4 levels indicated the poor prognosis of CCRCC patients. Accordingly, DUSP4 may be a promising biomarker for the prognosis of CCRCC.

In addition, it was found that DUSP4-overexpressed CCRCC cells showed higher proliferative and migratory levels. In contrast, CD142 knockdown was harmful to the proliferation and migration of CCRCC cells. Xenograft assays also showed that DUSP4-overexpressed CCRCC cells had the stronger tumorigenicity in vivo, while DUSP4-silenced CCRCC cells showed the reverse effect. Taken together, DUSP4 is likely to be an oncogenic gene and treatment target for CCRCC according to the evidence in vitro and in vivo. However, the intrinsic mechanism underlying DUSP4-regulated CCRCC carcinogenesis requires the further exploration.

Through this study, we revealed a novel biomarker for CCRCC, which may act as an oncogenic gene in the carcinogenesis of CCRCC. The detection of DUSP4 levels may be helpful to judge the prognosis of CCRCC. Moreover, targeting DUSP4 may be a potential treatment protocol for CCRCC. Based on current experimental data, the prognosis and treatment of CCRCC may be further improved in future.

Results
DUSP4 gene was overexpressed in the tissues and cell lines of CCRCC
Firstly, the GEPIA of TCGA database showed that the mRNA level of DUSP4 in CCRCC cancer tissues was significantly higher than that of paracancerous tissues (Fig. 1A). As shown in Fig. 1B, DUSP4 was significantly overexpressed in CCRCC tissue samples compared with paracancerous tissues. The correlation analyses related to clinical data showed that the increased DUSP4 levels was positively correlated with the growth, aggressiveness and metastasis of CCRCC cancer tissues (Table 1). Besides, 20 CCRCC samples with metastatic characteristic showed higher DUSP4 levels than 26 non-metastatic CCRCC samples (Fig. 1C). Moreover, compared with 21 CCRCC samples with a diameter less than 3 cm, 25 CCRCC samples with a diameter greater than 3 cm had higher DUSP4 expression (Fig. 1D). The detection of DUSP4 mRNA levels in normal renal tubular epithelial cell line HK-2 and CCRCC cell lines OS-RC-2, 786-O and Caki-1 showed that DUSP4 was significantly overexpressed in CCRCC cell lines (Fig. 1E).

**DUSP4 overexpression promoted the proliferation and migration of CCRCC cells while DUSP4 silencing showed the opposite effect**

To investigate the roles of DUSP4 in CCRCC, we overexpressed or silenced DUSP4 by transducing lentiviruses encoding DUSP4 (LV-DUSP4) or siRNAs against DUSP4 (si-DUSP4) into OS-RC-2 and 786-O cells (Fig. 2A,E). CCK-8 assays displayed that DUSP4 overexpression promoted the proliferative levels of OS-RC-2 and 786-O cells (Fig. 2B,F). In addition, Transwell assays showed that DUSP4 overexpression increased the number of migratory cells (Fig. 2C,D,G,H). By contrast, DUSP4 knockdown showed the opposite effects in the proliferative and migratory abilities of OS-RC-2 and 786-O cells (Fig. 2B-D, F-H).

**DUSP4 overexpression promoted the tumorigenicity of CCRCC cells in vivo while DUSP4 silencing showed the opposite effect**

To investigate the roles of DUSP4 in CCRCC in vivo, we injected DUSP4-overexpressed or DUSP4-silenced 786-O cells subcutaneously into nude mice. The import efficiency of DUSP4-overexpressed or DUSP4-silenced 786-O cells in xenograft tumors in vivo was verified by the results in Fig. 3A. As shown in Fig. 3B-D, DUSP4 overexpression significantly enhanced the sizes, growth curve and weights of CCRCC xenograft tumors, while DUSP4 knockdown showed the opposite results, which supports the promotional effect of DUSP4 gene on CCRCC tumorigenicity.

**Declarations**

**Author contributions** Xianxin Zhu and Xianyou Zeng conceived and designed experiments; Xianyou Zeng and Changyan Zhu performed experiments, analyzed data, and prepared figures; Xianxin Zhu wrote the manuscript.

**Funding** This work was supported by grants Basic Scientific Research Projects of Fujian Provincial Public Welfare Scientific Research Institutes (2016R1029-2).

**Data Availability** The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
Compliance with ethical standards

Conflict of interest No potential conflict of interest was disclosed by all authors.

Ethical approval All protocols of animal experiments were approved by the Institutional Animal Care and Use Committee of 900th Hospital of Joint Logistics Support Force. The Institutional Review Board of 900th Hospital of Joint Logistics Support Force reviewed and approved the collection and study of tumor samples.

Ethical approval Not applicable.

Consent to participate and publish This manuscript has been approved for submission and future publication by all authors.

References

1. Bhatt JR, Finelli a (2014) Landmarks in the diagnosis and treatment of renal cell carcinoma. Nat Rev Urol 11:517–525
2. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015) Global cancer statistics, 2012. CA Cancer J Clin 65:87–108
3. Barth DA, Slaby O, Klec C, Juracek J, Drula R, Calin GA, Pichler M (2019) Current Concepts of Non-Coding RNAs in the Pathogenesis of Non-Clear Cell Renal Cell Carcinoma. Cancers (Basel) 11:1580
4. Ljungberg B, Bensalah K, Canfield S, Darbani S, Hofmann F, Hora M, Kuczyk MA, Lam T, Marconi L, Merseburger AS, Mulders P, Powles T, Staehler M, Volpe A, Bex A (2015) EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol 67:913–924
5. Zhai W, Sun Y, Guo C, Hu G, Wang M, Zheng J, Lin W, Huang Q, Li G, Zheng J, Chang C (2017) LncRNA-SARCC suppresses renal cell carcinoma (RCC) progression via altering the androgen receptor(AR)/miRNA-143-3p signals. Cell Death Differ 24:1502–1517
6. BaKeR H (2016) Sunitinib as adjuvant therapy for renal cell carcinoma. Lancet Oncol 17:e485
7. Low HB, Zhang Y (2016) Regulatory Roles of MAPK Phosphatases in Cancer. Immune Netw 16:85–98
8. Prabhakar S, Asuthkar S, Lee W, Chigurupati S, Zakharian E, Tsung AJ, Velpula KK (2014) Targeting DUSPs in glioblastomas-wielding a double-edged sword? Cell Biol Int 38:145–153
9. Balko JM, Schwarz LJ, Bhola NE, Kurupi R, Owens P, Miller TW, Gómez H, Cook RS, Arteaga CL (2013) Activation of MAPK pathways due to DUSP4 loss promotes cancer stem cell-like phenotypes in basal-like breast cancer. Cancer Res 73:6346–6358
10. Barajas-Espinosa A, Basye A, Angelos MG, Chen CA (2015) Modulation of p38 kinase by DUSP4 is important in regulating cardiovascular function under oxidative stress. Free Radic Biol Med 89:170–181
11. Kim SY, Han YM, Oh M, Kim WK, Oh KJ, Lee SC, Bae KH, Han BS (2015) DUSP4 regulates neuronal differentiation and calcium homeostasis by modulating ERK1/2 phosphorylation. Stem Cells Dev 24:686–700

12. Denhez B, Rousseau M, Dancosst DA, Lizotte F, Guay A, Auger-Messier M, Côté AM, Geraldes P (2019) Diabetes-Induced DUSP4 Reduction Promotes Podocyte Dysfunction and Progression of Diabetic Nephropathy. Diabetes 68:1026–1039

13. Hijiya N, Tsukamoto Y, Nakada C, Tung Nguyen L, Kai T, Matsuura K, Shibata K, Inomata M, Uchida T, Tokunaga A, Amada K, Shirao K, Yamada Y, Mori H, Takeuchi I, Seto M, Aoki M, Takekawa M, Moriyama M (2016) Genomic Loss of DUSP4 Contributes to the Progression of Intraepithelial Neoplasm of Pancreas to Invasive Carcinoma. Cancer Res 76:2612–2625

14. Schmid CA, Robinson MD, Scheifinger NA, Müller S, Cogliatti S, Tzankov A, Müller A (2015) DUSP4 deficiency caused by promoter hypermethylation drives JNK signaling and tumor cell survival in diffuse large B cell lymphoma. J Exp Med 2125:775–792

15. Xu X, Gao F, Wang J, Tao L, Ye J, Ding L, Ji W, Chen X (2018) MiR-122-5p inhibits cell migration and invasion in gastric cancer by down-regulating DUSP4. Cancer Biol Ther 19:427–435

16. Ma B, Shi R, Yang S, Zhou L, Qu N, Liao T, Wang Y, Wang Y, Ji Q (2016) DUSP4/MKP2 overexpression is associated with BRAF(V600E) mutation and aggressive behavior of papillary thyroid cancer. Onco Targets Ther 9:2255–2263

17. Gröschl B, Bettstetter M, Giedl C, Woenckhaus M, Edmonston T, Hofstädter F, Dietmaier W (2013) Expression of the MAP kinase phosphatase DUSP4 is associated with microsatellite instability in colorectal cancer (CRC) and causes increased cell proliferation. Int J Cancer 132:1537–1546